188 related articles for article (PubMed ID: 23391656)
1. [Usefulness of serum free light-chain assay for evaluation of therapeutic efficacy in non-secretory multiple myeloma].
Maruyama Y; Hayashi T; Ikeda H; Yasui H; Ishida T; Shinomura Y
Rinsho Ketsueki; 2013 Jan; 54(1):122-6. PubMed ID: 23391656
[TBL] [Abstract][Full Text] [Related]
2. Development of a highly-sensitive multi-plex assay using monoclonal antibodies for the simultaneous measurement of kappa and lambda immunoglobulin free light chains in serum and urine.
Campbell JP; Cobbold M; Wang Y; Goodall M; Bonney SL; Chamba A; Birtwistle J; Plant T; Afzal Z; Jefferis R; Drayson MT
J Immunol Methods; 2013 May; 391(1-2):1-13. PubMed ID: 23388695
[TBL] [Abstract][Full Text] [Related]
3. Clinical usefulness of free light chain concentration as a tumor marker in multiple myeloma.
Kang SY; Suh JT; Lee HJ; Yoon HJ; Lee WI
Ann Hematol; 2005 Sep; 84(9):588-93. PubMed ID: 15883850
[TBL] [Abstract][Full Text] [Related]
4. Polyclonal free light chain of Ig may interfere with interpretation of monoclonal free light chain κ/λ ratio.
Levinson SS
Ann Clin Lab Sci; 2010; 40(4):348-53. PubMed ID: 20947809
[TBL] [Abstract][Full Text] [Related]
5. Detection of kappa and lambda light chain monoclonal proteins in human serum: automated immunoassay versus immunofixation electrophoresis.
Jaskowski TD; Litwin CM; Hill HR
Clin Vaccine Immunol; 2006 Feb; 13(2):277-80. PubMed ID: 16467338
[TBL] [Abstract][Full Text] [Related]
6. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders.
Dispenzieri A; Kyle R; Merlini G; Miguel JS; Ludwig H; Hajek R; Palumbo A; Jagannath S; Blade J; Lonial S; Dimopoulos M; Comenzo R; Einsele H; Barlogie B; Anderson K; Gertz M; Harousseau JL; Attal M; Tosi P; Sonneveld P; Boccadoro M; Morgan G; Richardson P; Sezer O; Mateos MV; Cavo M; Joshua D; Turesson I; Chen W; Shimizu K; Powles R; Rajkumar SV; Durie BG;
Leukemia; 2009 Feb; 23(2):215-24. PubMed ID: 19020545
[TBL] [Abstract][Full Text] [Related]
7. Quantitative serum free light chain assay in the diagnostic evaluation of AL amyloidosis.
Akar H; Seldin DC; Magnani B; O'Hara C; Berk JL; Schoonmaker C; Cabral H; Dember LM; Sanchorawala V; Connors LH; Falk RH; Skinner M
Amyloid; 2005 Dec; 12(4):210-5. PubMed ID: 16399645
[TBL] [Abstract][Full Text] [Related]
8. [Progress in the management of multiple myeloma introduced by serum free light chain measurement].
Fuchida S; Shimazaki C
Nihon Rinsho; 2011 Dec; 69(12):2267-73. PubMed ID: 22242331
[TBL] [Abstract][Full Text] [Related]
9. [Evaluation of the clinical relevance of serum measurements of free-light chains in patients with multiple myeloma].
Shimizu K; Itoh J; Sugiura I; Tsushita K; Kosugi H; Nagura E
Rinsho Ketsueki; 2006 Apr; 47(4):303-9. PubMed ID: 16715965
[TBL] [Abstract][Full Text] [Related]
10. The evolving use of serum free light chain assays in haematology.
Pratt G
Br J Haematol; 2008 May; 141(4):413-22. PubMed ID: 18318757
[TBL] [Abstract][Full Text] [Related]
11. New patterns of relapse in multiple myeloma: a case of "light chain escape" in which FLC predicted relapse earlier than urine and serum immunofixation.
Caldini A; Nozzoli C; Terreni A; Staderini M; Berardi M; Biagioli T; Brogi M; Bosi A
Clin Chem Lab Med; 2016 Jun; 54(6):991-5. PubMed ID: 26581069
[TBL] [Abstract][Full Text] [Related]
12. Assessing the efficiency of free light chain assay in monitoring patients with multiple myeloma before and after autologous stem cell transplantation along with serum protein electrophoresis and serum protein immunofixation.
Dogaru M; Lazăr V; Coriu D
Roum Arch Microbiol Immunol; 2011; 70(1):15-22. PubMed ID: 21717807
[TBL] [Abstract][Full Text] [Related]
13. Serum free light chains for monitoring multiple myeloma.
Mead GP; Carr-Smith HD; Drayson MT; Morgan GJ; Child JA; Bradwell AR
Br J Haematol; 2004 Aug; 126(3):348-54. PubMed ID: 15257706
[TBL] [Abstract][Full Text] [Related]
14. Assessment of serum free light chain assays for plasma cell disorder screening in a Veterans Affairs population.
Abadie JM; Bankson DD
Ann Clin Lab Sci; 2006; 36(2):157-62. PubMed ID: 16682511
[TBL] [Abstract][Full Text] [Related]
15. [Assessment of serum free light chain of patients with multiple myeloma and clinical significance thereof].
Sui WW; Yao HJ; Wang YF; Wang L; Zhang K; Xu Y; Qiu LG
Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(44):3158-60. PubMed ID: 18269880
[TBL] [Abstract][Full Text] [Related]
16. [Serum free light chains for diagnosis and follow-up of multiple myeloma].
Jung S; Kim M; Lim J; Kim Y; Han K; Min CK; Min WS
Korean J Lab Med; 2008 Jun; 28(3):169-73. PubMed ID: 18594166
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic performance of quantitative kappa and lambda free light chain assays in clinical practice.
Katzmann JA; Abraham RS; Dispenzieri A; Lust JA; Kyle RA
Clin Chem; 2005 May; 51(5):878-81. PubMed ID: 15774572
[TBL] [Abstract][Full Text] [Related]
18. Assessment of the analytical performance and the sensitivity of serum free light chains immunoassay in patients with monoclonal gammopathy.
Wolff F; Thiry C; Willems D
Clin Biochem; 2007 Mar; 40(5-6):351-4. PubMed ID: 17239359
[TBL] [Abstract][Full Text] [Related]
19. Serum free light chains: diagnostic and prognostic value in multiple myeloma.
Sthaneshwar P; Nadarajan V; Maniam JA; Nordin N; Gin Gin G
Clin Chem Lab Med; 2009; 47(9):1101-7. PubMed ID: 19728852
[TBL] [Abstract][Full Text] [Related]
20. Quantification of serum free light chain kappa and lambda by the SPAPLUS analyser.
Maisin D; Lepoutre T; Gruson D; Wallemacq P
Clin Biochem; 2013 May; 46(7-8):622-6. PubMed ID: 23291296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
